A
Astria Therapeutics
Biotech & Life Sciences · Boston, United States · Founded 2008 · IPO 2015
Catabasis Pharmaceuticals discovers and develops innovative drugs for treating inflammatory conditions MoreLess
Astria Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for allergic and immunological diseases.
The company's lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of Hereditary Angioedema (HAE), a rare genetic disorder characterized by severe and recurrent episodes of swelling.
Astria is also developing other preclinical programs for the treatment of allergic and immunologic diseases. The company's business model is based on developing and commercializing its product candidates, either on its own or in collaboration with other pharmaceutical companies. Astria's target market is the global market for HAE and other allergic and immunologic diseases, which is estimated to be worth billions of dollars.
Keywords: Biopharmaceutical, Allergic Diseases, Immunological Diseases, Hereditary Angioedema, Monoclonal Antibody, Plasma Kallikrein, Clinical Trials, Drug Development, Therapeutics, Healthcare
Company overview
Astria Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2008
- Headquarters
- Boston, United States
- Employees
- 120
- Open positions
- None listed
- Dealroom signal
- 61.1
- Investment activity
- 1 companies · latest Feb 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Astria Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Oct 2025 | $700M | $700M | BioCryst Pharmaceuticals | ↗ |
| POST IPO EQUITY✓Other financing | Jan 2024 | $125M | — | Adage Capital · Perceptive Advisors · Driehaus Capital Management · RA Capital Management | ↗ |
| POST IPO EQUITY✓Other financing | Oct 2023 | $64M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Jun 2018 | $42M | — | Undisclosed | — |
| POST IPO EQUITY✓Other financing | Sep 2016 | $12M | — | Undisclosed | — |
| IPO✓Exit | Jun 2015 | Undisclosed | — | ||
| SERIES A✓Equity / VC | Apr 2010 | MedImmune Ventures · Advanced Technology Ventures · Clarus Ventures · SV Health Investors | — | ||
| DEBT✓Debt | Jan 2010 | Undisclosed | — | ||
| DEBT✓Debt | Jan 2010 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Astria Therapeutics website traffic
Latest recorded traffic for Astria Therapeutics is 3.6K monthly website visits, up 2.9% over the last three months. Astria Therapeutics's team grew 0% over the past year.
Comparisons
Astria Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Astria Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Astria Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Astria Therapeutics has talent and traffic
team presence
In the news
Latest news about Astria Therapeutics
Recent press, funding announcements, and product moves mentioning Astria Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Astria Therapeutics
An AI-synthesized read of the highest-engagement posts about Astria Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Astria Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.